Author:
Del Mastro L, ,Bruzzi P,Nicolò G,Cavazzini G,Contu A,D'Amico M,Lavarello A,Testore F,Castagneto B,Aitini E,Perdelli L,Bighin C,Rosso R,Venturini Marco
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H (1991) ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6: 137–143
2. Citron CL, Berry DA, Cirrincione C, Hudis C, Winer EO, Gradishar MJ, Davidson NE, Martino S, Livingstone R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton I (2003) Randomized trial of dose-dense vs conventionally scheduled and sequential vs concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439
3. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ (2002) HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8: 1107–1116
4. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting Highlights: updated international export consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357–3365
5. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N (1998) ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361–1370
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献